Incidence and clinical impact of chemotherapy induced myelotoxicity in cancer patients: An observational retrospective survey
Introduction
Anemia and neutropenia are frequent myelotoxic events responsible for chemotherapy delays, discontinuations and dose modifications. As they can impair the efficacy of chemotherapy, a great efforts have being made to minimise the risk of morbidity and mortality [1], [2].
The Functional Assessment of Cancer Therapy-Anaemia (FACT-An) validation study suggested a relationship between hemoglobin (Hb) levels and patients’ quality of life, as the patients with Hb ≥ 12 g/dL had a significantly higher mean FACT-An score than those with Hb < 12 g/dL [3].
The European Cancer Anaemia Survey (ECAS) investigated the prevalence, incidence and treatment of anemia in 15,367 cancer patients evaluated for up to six months [4]. The prevalence of anemia was 39.3% at enrolment and 67.0% during the survey, and its incidence was 53.7%. Anemia was treated in 38.9% of the patients (erythropoietic agents 17.4%; transfusions 14.9%; and iron 6.5%), and the mean hemoglobin level for starting treatment was 9.7 g/dL. These results are consistent with the findings of Seshadri et al. [5] concerning 694 Australian patients with a median age of 60 years. Anemia was observed in 57% of the patients and was consistent with tumour type (49% of the patients with lymphoma and myeloma, 85% of those with urogenital cancer). Anemia was treated by transfusions in 36% of the patients, and by iron in 5%; a further 2% were treated with erythropoietic agents. The frequency of anemia treatment varied among tumour types, from 19% (breast cancer) to 60% (leukemia).
Neutropenia is a frequent complication of chemotherapy. Caggiano et al. [6] carried out a retrospective analysis to evaluate the incidence, mortality and hospitalisation associated with neutropenia. There were 20,780 discharges with documentation of cancer chemotherapy and neutropenia. The incidence of hospitalisation due to neutropenia projected to national levels was estimated at 60,294 cases (7.83 cases per 1000 cancer patients), and the mortality rate was estimated at 6.8% (1 death for every 14 hospitalised patients). As expected, neutropenia hospitalisation was particularly common in patients with hematological tumours, with an incidence of 43.3 cases per 1000 patients.
In the last decade, the use of recombinant human erythropoietins (rHuEPO) and granulocyte-colony stimulating factors (G-CSFs) has radically modified the treatment of myelotoxicity due to chemotherapy in clinical practice. The reported response to rHuEPO (defined as an increase in Hb of >2 g/dL) ranges from 32 to 82% [7], and rHuEPO are widely used for cancer-related treatment of anemia in many countries [8], [9], [10], [11]. Recently, concerns about the safety of rHuEPO have been raised and the need to redefine the exact setting for its use has been claimed [12]. However serious risk with the rHuEPO have been observed in clinical setting and hemoglobin ranges not supported by current guidelines [13].
G-CSFs have provided considerable benefits to patients treated with chemotherapy and represent the standard treatment for chemotherapy-induced neutropenia [14], [15], [16], [17], [18], [19].
However, although several guidelines, consensus conferences and authoritative publications are now available for practising physicians, many questions remain open, and the standard approach to the management of cancer-related anemia and neutropenia is far from being defined [20], [21], [22], [23], [24].
On the basis of these previous experiences, CIPOMO (Collegio Italiano Primari Oncologi Medici Ospedalieri) conducted this retrospective observational survey in order to collect information concerning the prevalence and incidence of myelotoxicity, anemia and neutropenia in Italian Community Hospitals, and treatment patterns in cancer patients receiving chemotherapy.
Section snippets
Patients
The study data referred to 1175 patients attending 64 Italian Centres belonging to CIPOMO between July 2005 to January 2006.
The objectives of the study were to evaluate: (i) the frequency of the diagnoses of anemia and neutropenia in patients treated with chemotherapy; (ii) the prescribed treatment for anemia and neutropenia and (iii) the occurrence of chemotherapy dose reductions, delays or discontinuations due to anemia and/or neutropenia.
The eligible patients were >18 year old and had a
Results
Table 1 shows the patients’ characteristics. There were more females in the adult group (73.2% females vs 26.8% males) but no gender difference in the elderly group.
The most frequent cancer site was the breast (390 patients, 33.2%) followed by colon–rectum (299 patients, 25.5%), non-small cell lung cancer (113 patients, 9.6%), ovary (84 patients, 7.1%) and stomach (46 patients, 3.9%). There were more patients with breast cancer in the adult group, and more patients with colon–rectum and NSCLC
Discussion
This retrospective observational survey explored the prevalence and incidence of myelotoxicity, anemia and neutropenia in an Italian population of 1175 cancer patients, treated in Community Hospitals, in accordance with local rules and physician judgment.
In terms of age, the distribution of tumour types and treatments, our population appears to be representative of the general cancer population, as indicated by epidemiological studies [25].
The survey showed that 53.9% of the patients
Conflict of interest
Author has no conflicting interest to declare.
Reviewer
Heidi D. Klepin, M.D., Wake Forest University School of Medicine, Section of Hematology and Oncology, Medical Center Boulevard, Winston-Salem, NC 27157, United States.
Acknowledgments
The authors would like to thank Dr. Simonetta Pignattelli (Medical Affairs, AMGEN, Italy) for supporting the study, Dr. Patrizio Sala, for the statistical analyses, and Dr. Ettore Bichisao for his help in preparing the manuscript. The full list of all the participating CIPOMO Centres is given in Appendix A.
Lazzaro Repetto is Director of Medical Oncology at the Istituto Nazionale Riposo e Cura per Anziani, INRCA—Rome since 2001. After medical degree at the University of Genoa in 1982 he completed his medical training as Fellow of the Department of Hematology University of Genoa, the Department of Medical Oncology Istituto Nazionale per la Ricerca sul Cancro Genoa, and the Department of Medical Oncology at Royal Marsden Hospital, London.
He held the positions of assistant professor and deputy head,
References (27)
- et al.
Myelotoxicity from chemotherapy
Semin Oncol
(2006) - et al.
Trends in recommendations of myelosuppressive chemotherapy for the treatment of breast cancer: evolution of the national comprehensive cancer network guidelines and the cooperative group studies
Clin Breast Cancer
(2006) - et al.
The European Cancer of Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients
Eur J Cancer
(2004) Recombinant human erythropoietin in oncology: current status and further developments
Ann Oncol
(2005)- et al.
Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin
Exp Hematol
(2003) - et al.
Neulasta (pegfilgrastim): a once-per-cycle option for the management of chemotherapy-induced neutropenia
Semin Oncol
(2004) - et al.
Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer
Ann Oncol
(2002) Current management of chemotherapy-induced neutropenia: the role of colony-stimulating factors
Semin Oncol
(2003)- et al.
EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer
Eur J Cancer
(2007) - et al.
EORTC guidelines for the use of granulocyte colony stimulating factor to reduce the incidence of chemotherapy induced febrile neutropenia in adult patients with lymphomas and solid tumours
Eur J Cancer
(2006)
Estimates of the cancer incidence and mortality in Europe in 2006
Ann Oncol
The Functional Assessment of Cancer Therapy-Anaemia (FACT-An) Scale: a new tool for the assessment of the outcomes in cancer anaemia and fatigue
Semin Haematol
The Australian Cancer Anaemia Survey: a snapshot of anaemia in adult patients with cancer
MJA
Cited by (41)
Molecular design, synthesis and anticancer activity of new thiopyrano[2,3-d]thiazoles based on 5-hydroxy-1,4-naphthoquinone (juglone)
2023, European Journal of Medicinal ChemistryImpact of chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN) on cancer treatment outcomes: An overview about well-established and recently emerging clinical data
2017, Critical Reviews in Oncology/HematologyCitation Excerpt :Finally, in a retrospective analysis about data of 1175 patients, who completed at least four chemotherapy courses for solid tumors, dose reductions were observed in 17%, dose delays in 29%, and treatment discontinuation in 13%. A significant association between chemotherapy dose delays, dose reductions and myelotoxicity has been established (p < 0.001) (Repetto, 2009). Moreover, such similar results have been found in other large retrospective studies focusing on chemotherapy administration among NHL patients (Picozzi et al., 2001; Lyman et al., 2004).
Regulation of Immune Function of Cyclophosphamide-induced Immunosuppressed Mice by Five Plant Polysaccharides: A Network Meta-analysis
2023, Chinese Journal of Experimental Traditional Medical FormulaeCarbohydrates and ginsenosides in shenmai injection jointly improve hematopoietic function during chemotherapy-induced myelosuppression in mice
2022, Chinese Medicine (United Kingdom)
Lazzaro Repetto is Director of Medical Oncology at the Istituto Nazionale Riposo e Cura per Anziani, INRCA—Rome since 2001. After medical degree at the University of Genoa in 1982 he completed his medical training as Fellow of the Department of Hematology University of Genoa, the Department of Medical Oncology Istituto Nazionale per la Ricerca sul Cancro Genoa, and the Department of Medical Oncology at Royal Marsden Hospital, London.
He held the positions of assistant professor and deputy head, Department of Medical Oncology Istituto Nazionale per la Ricerca sul Cancro Genoa.
He is member of several scientific societies and author of 180 papers.
- 1
Collegio Italiano Primari Oncologi Medici Ospedalieri investigators.